公开(公告)号：US20210301020A1

公开(公告)日：2021-09-30

申请号：US17262339

申请日：2019-07-17

Applicant: AMGEN INC.

Inventor： Xin YU ,  Wenjun OUYANG ,  Chi-Ming Kevin LI ,  Jackson Graeme EGEN ,  Oh Kyu YOON ,  Ian Halsey DRIVER ,  Shunsuke TAKENAKA ,  Christy Ann THOMSON ,  Hongyu WANG

IPC: C07K16/28 ,  A61P35/00

Abstract: This invention relates to combination therapies comprising a Programmed Death 1 receptor (PD-1) pathway inhibitor, and a Leukocyte Immunoglobulin Like Receptor B (LILRB) signaling inhibitor, and the use of the combination therapies for the treatment of cancer. The invention also relates to the treatment of cancer patients who are refractory to monotherapy with a PD-1 pathway inhibitor.

公开(公告)号：US20170253889A1

公开(公告)日：2017-09-07

申请号：US15519820

申请日：2015-10-14

Applicant: AMGEN INC.

Inventor： Mark DARIS ,  Jennitte LeAnn STEVENS ,  Chi-Ming Kevin LI ,  Huanying GE

IPC: C12N15/85 ,  C12N9/02

CPC classification number: C12N15/85 ,  C07K14/47 ,  C12N9/0008 ,  C12N9/88 ,  C12N2830/00 ,  C12N2830/15 ,  C12N2830/34 ,  C12N2830/42 ,  C12N2830/85 ,  C12Y102/01012

Abstract: Disclosed are a recombinant expression vector and a host cell that contains the vector.